Lung Cancer News and Research

Latest Lung Cancer News and Research

Majority of cancer patients are concerned about treatment costs: MDLinx

Ninety five percent of the nation's oncologists report a rise in their patients' concerns over treatment costs in the past six months, according to a survey conducted by MDLinx, one of the U.S.'s largest doctor portals.

7 Oct 2010

Sudden cardiac arrest survivors to gather at SCAA Annual Meeting

A nationwide gathering of sudden cardiac arrest (SCA) survivors, emergency responders and civilian rescuers will mark SCA Awareness Month with a Survivors & Heroes Celebration on Friday, October 8 at 6:00 p.m. at the Marriott City Center in Pittsburgh, Pennsylvania.

7 Oct 2010

American Cancer Society awards 94 national research, training grants to 70 institutions nationwide

The American Cancer Society, the largest non-government, not-for-profit funding source of cancer research in the United States, has awarded 94 national research and training grants totaling $46,633,000 to 70 institutions nationwide in the first of two grants cycles for 2011.

7 Oct 2010

Optical technology shows potential for prescreening patients at high risk for lung cancer

Researchers from Northwestern University and NorthShore University HealthSystem (NorthShore) have developed a method to detect early signs of lung cancer by examining cheek cells in humans using pioneering biophotonics technology.

6 Oct 2010

Knome announces winners of KnomeDISCOVERY Awards

Knome, Inc. today announced the winners of its inaugural KnomeDISCOVERY Awards, a program designed to spur new genetic insights into health.

6 Oct 2010

Merck Serono to present Erbitux data at ESMO Congress

Merck Serono, a division of Merck KGaA, Darmstadt, Germany announces today that it will be presenting new data from several studies of Erbitux (cetuximab) in a range of solid tumor types including the first Phase II data in breast and prostate cancers. These data will be presented at the forthcoming 35th European Society for Medical Oncology Congress (ESMO) in Milan, October 8-12, 2010.

5 Oct 2010

Decision Resources: NSCLC drug market to grow from $4 billion in 2009 to over $6.5 billion in 2019

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues finds that the non-small-cell lung cancer (NSCLC) drug market will increase from approximately $4 billion in 2009 to more than $6.5 billion in 2019 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan.

4 Oct 2010

Rate of chemotherapy administration for NSCLC more than twice that reported by SEER

For the first time to date, research published in the October edition of the Journal of Thoracic Oncology (JTO) sought to determine the use of chemotherapy in a contemporary, diverse non-small cell lung cancer (NSCLC) population encompassing all patient ages. Prior population-based studies have shown that only 20 to 30 percent of advanced lung cancer patients receive chemotherapy treatment.

4 Oct 2010

Benitec announces USPTO's reversal of all previous rejections in '099 Graham patent appeal

Benitec Limited, a leading Australian based company specialising in RNA interference (RNAi) technology is pleased to announce the United States Patent and Trademark Office's (USPTO) Board of Patent Appeals and Interferences decision ("the Decision") reversing all previous rejections in the US 6,573,099 (the '099 Graham patent) appeal.

4 Oct 2010

AVEO Pharmaceuticals to present tivozanib Phase 2 study results at IKCS Symposium

AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that previously reported results from its Phase 2 study evaluating tivozanib for the treatment of advanced renal cell carcinoma (RCC) will be presented at the Ninth International Kidney Cancer Symposium (IKCS) in Chicago, Illinois, October 1-2, 2010.

4 Oct 2010

Sanofi-aventis publishes Phase III TROPIC study data in The Lancet article

Sanofi-aventis announced today that data from the Phase III TROPIC study, which was the basis for the June 2010 U.S. Food and Drug Administration (FDA) approval of Jevtana (cabazitaxel) Injection, was published in the October 2, 2010 print edition of The Lancet in an article titled "Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.

4 Oct 2010

PDGFR gene rearrangements lead to aggressive form of glioblastoma: Study

4 Oct 2010

Activating rearrangements in receptor genes are more common than previously thought

A multi-institutional team led by investigators from Memorial Sloan-Kettering Cancer Center has published a study that provides new insight into genetic changes that make some forms of glioblastoma, the most common type of primary brain cancer, more aggressive than others and explains why they may not respond to certain therapies. The research was led by senior author Eric C. Holland, MD, PhD,--an MSKCC surgeon, researcher and the Director of the Brain Tumor Center--and was published in the October 1 issue of the journal Genes & Development.

1 Oct 2010

Increase in excise taxes and state-of-the-art tobacco control program reduces lung cancer rates

A study led by researchers at the University of California, San Diego shows that California's 40 year-long tobacco control program has resulted in lung cancer rates that are nearly 25 percent lower than other states.

1 Oct 2010

Global phase IV study confirms efficacy of erlotinib in treatment of non-small cell lung cancer

Featured in the October edition of the Journal of Thoracic Oncology (JTO), data from The Tarceva Lung Cancer Survival Treatment (TRUST) confirms the safety and efficacy profile of erlotinib, a highly potent oral active, reversible inhibitor of epidermal growth factor receptor (EGFR) tyrosine-kinase (TK) activity in a large heterogeneous non-small cell lung cancer (NSCLC) population.

1 Oct 2010

Teva Pharmaceuticals, OncoGenex initiate SYNERGY Phase 3 trial to evaluate custirsen

Teva Pharmaceuticals Industries Ltd. and OncoGenex Pharmaceuticals, Inc. announced today the initiation of SYNERGY, a global Phase 3 trial evaluating custirsen (also known as OGX-011/TV-1011) as first line therapy for the treatment of castrate-resistant prostate cancer (CRPC).

30 Sep 2010

AVEO regains global rights for development, commercialization of AV-299 anti-HGF antibody candidate

AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that AVEO has regained worldwide rights from Merck (through its subsidiary, Schering Corporation) to develop and commercialize AV-299 (also known as SCH 900105), its anti-hepatocyte growth factor (HGF) antibody candidate.

30 Sep 2010

Lung Cancer News and Research

Latest Lung Cancer News and Research

Majority of cancer patients are concerned about treatment costs: MDLinx

Sudden cardiac arrest survivors to gather at SCAA Annual Meeting

American Cancer Society awards 94 national research, training grants to 70 institutions nationwide

Optical technology shows potential for prescreening patients at high risk for lung cancer

Knome announces winners of KnomeDISCOVERY Awards

Merck Serono to present Erbitux data at ESMO Congress

Decision Resources: NSCLC drug market to grow from $4 billion in 2009 to over $6.5 billion in 2019

Rate of chemotherapy administration for NSCLC more than twice that reported by SEER

Benitec announces USPTO's reversal of all previous rejections in '099 Graham patent appeal

AVEO Pharmaceuticals to present tivozanib Phase 2 study results at IKCS Symposium

Sanofi-aventis publishes Phase III TROPIC study data in The Lancet article

PDGFR gene rearrangements lead to aggressive form of glioblastoma: Study

Activating rearrangements in receptor genes are more common than previously thought

Increase in excise taxes and state-of-the-art tobacco control program reduces lung cancer rates

Global phase IV study confirms efficacy of erlotinib in treatment of non-small cell lung cancer

Teva Pharmaceuticals, OncoGenex initiate SYNERGY Phase 3 trial to evaluate custirsen

AVEO regains global rights for development, commercialization of AV-299 anti-HGF antibody candidate

Study shows tobacco control program reduces lung cancer rate

MicroRNAs assay may allow better targeted therapy for lung cancer patients

AACR to host Third Conference on The Science of Cancer Health Disparities

The ultimate guide to lung research tools and protocols eBook

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Lung Cancer News and Research

Latest Lung Cancer News and Research

The ultimate guide to lung research tools and protocols eBook

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in